reports
A director bought 25,000 shares at 0.980USD and
A director at Curis Inc bought 25,000 shares at 0.980USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
LENEXA, Kan.--(BUSINESS WIRE)-- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer. As the cancer immunotherapy space continues to evolve, research-centric biotechnology companies that specialize in immunotherapy are more numerous, innovative, and have a larger role to play in the field’s ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.